A Payer Perspective of the Hospital Inpatient Additional Care Costs of Antimicrobial Resistance in France: A Matched Case–Control Study

Touat, Mehdi; Opatowski, Marion; Brun‐Buisson, Christian; Cosker, K.; Guillemot, Didier; Salomon, Jérôme; Tuppin, Philippe; Lagasnerie, Grégoire de; Watier, Laurence

doi:10.1007/s40258-018-0451-1

Cited by 34 publications

(22 citation statements)

References 32 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A separate approach has been to rely on national [48,52,53,55] or global [19,20] surveillance databases rather than individual sites. This offers greater external validity but may only be accurate in countries with representative patient data on healthcare utilisation, prescribing and antibiotic susceptibility, ideally linked to account for dependencies in these variables.…”

Section: Extension In Space: From One Hospital To National/global Estmentioning

confidence: 99%

Quantifying the economic cost of antibiotic resistance and the impact of related interventions: rapid methodological review, conceptual framework and recommendations for future studies

Jit

Luangasanatip

et al. 2020

BMC Med

View full text Add to dashboard Cite

Background: Antibiotic resistance (ABR) poses a major threat to health and economic wellbeing worldwide. Reducing ABR will require government interventions to incentivise antibiotic development, prudent antibiotic use, infection control and deployment of partial substitutes such as rapid diagnostics and vaccines. The scale of such interventions needs to be calibrated to accurate and comprehensive estimates of the economic cost of ABR.Methods: A conceptual framework for estimating costs attributable to ABR was developed based on previous literature highlighting methodological shortcomings in the field and additional deductive epidemiological and economic reasoning. The framework was supplemented by a rapid methodological review.Results: The review identified 110 articles quantifying ABR costs. Most were based in high-income countries only (91/110), set in hospitals (95/110), used a healthcare provider or payer perspective (97/110), and used matched cohort approaches to compare costs of patients with antibiotic-resistant infections and antibiotic-susceptible infections (or no infection) (87/110). Better use of methods to correct biases and confounding when making this comparison is needed. Findings also need to be extended beyond their limitations in (1) time (projecting present costs into the future), (2) perspective (from the healthcare sector to entire societies and economies), (3) scope (from individuals to communities and ecosystems), and (4) space (from single sites to countries and the world). Analyses of the impact of interventions need to be extended to examine the impact of the intervention on ABR, rather than considering ABR as an exogeneous factor. Conclusions:Quantifying the economic cost of resistance will require greater rigour and innovation in the use of existing methods to design studies that accurately collect relevant outcomes and further research into new techniques for capturing broader economic outcomes.

show abstract

Section: Extension In Space: From One Hospital To National/global Estmentioning

confidence: 99%

Quantifying the economic cost of antibiotic resistance and the impact of related interventions: rapid methodological review, conceptual framework and recommendations for future studies

Jit

Luangasanatip

et al. 2020

BMC Med

View full text Add to dashboard Cite

show abstract

“…ESKAPEE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp., and Escherichia coli) play a prominent role in this global epidemic and are considered by the WHO as high-risk pathogens [3][4][5][6]. Alone in the EU antibiotic resistant, microbes cause reportedly disability, mortality, and increasing costs in medical care [7][8][9]. In the recent history, there is still no single multi-drug-resistant microorganism capable of causing a pandemic like the coronavirus disease 2019 (COVID-19) [10].…”

Section: Introductionmentioning

confidence: 99%

“Smart” Antimicrobial Nanocomplexes with Potential to Decrease Surgical Site Infections (SSI)

et al. 2020

View full text Add to dashboard Cite

The emergence of resistant pathogens is a burden on mankind and threatens the existence of our species. Natural and plant-derived antimicrobial agents need to be developed in the race against antibiotic resistance. Nanotechnology is a promising approach with a variety of products. Biosynthesized silver nanoparticles (AgNP) have good antimicrobial activity. We prepared AgNPs with trans-cinnamic acid (TCA) and povidone-iodine (PI) with increased antimicrobial activity. We synthesized also AgNPs with natural cinnamon bark extract (Cinn) in combination with PI and coated biodegradable Polyglycolic Acid (PGA) sutures with the new materials separately. These compounds (TCA-AgNP, TCA-AgNP-PI, Cinn-AgNP, and Cinn-AgNP-PI) and their dip-coated PGA sutures were tested against 10 reference strains of microorganisms and five antibiotics by zone inhibition with disc-and agar-well-diffusion methods. The new compounds TCA-AgNP-PI and Cinn-AgNP-PI are broad spectrum microbicidal agents and therefore potential coating materials for sutures to prevent Surgical Site Infections (SSI). TCA-AgNP-PI inhibits the studied pathogens stronger than Cinn-AgNP-PI in-vitro and on coated sutures. Dynamic light scattering (DLS), ultraviolet-visible spectroscopy (UV-Vis), Fourier Transform infrared spectroscopy (FT-IR), Raman, X-ray diffraction (XRD), microstructural analysis by scanning electron microscopy (SEM) and energy dispersive spectroscopy (EDS) confirmed the composition of TCA-AgNP-PI and Cinn-AgNP-PI. Smart solutions involving hybrid materials based on synergistic antimicrobial action have promising future perspectives to combat resistant microorganisms.Pharmaceutics 2020, 12, 361 2 of 36 20,000 related deaths in the United States in 2017 only and remains to be one of the important infection-associated mortality reasons [11,12]. The formation of biofilms on biotic and abiotic surfaces [13] paved the way for biofilm antibiotic tolerance as another major health threat [14,15]. This additional problem hampers the treatment of infections, most often gives rise to chronic infections, in the worst case to therapeutic failure, severe morbidity, and mortality [4]. More than 80% of microbial infections are caused by microbial biofilm formation and pose a severe health risk because treatment with antibiotics remains ineffective [16]. The incidence of chronic wound infections is increasing globally to alarming levels [17]. Chronic wounds are marked by high bacterial colonization and infection rates, which can be treated only by novel therapeutic approaches other than the use of conventional antibiotics [18,19]. Chronic wound tissues can contain microbiomes of complex communities with coexisting fungal and bacterial colonies of different strains within biofilms [20]. According to this inter-kingdom model, fungi like Candida albicans can offer structures for other bacteria (S. aureus, P. aeruginosa, Streptococcus spp., E. faecalis, E. coli, and Acinetobacter baumannii etc.) to attach, form intricate biofilms, and increase the resistance against any ...

show abstract

“…Global data are alarming: drug-resistant infections are responsible for one death every 45 s in the world [13]. Besides this high increase in mortality and morbidity rates, antibiotic resistance also generates a high additional economic burden, reaching up to 20 billion dollars for the U. S. healthcare system [12,14,15].…”

Section: Eskapee Pathogenic Bacteriamentioning

confidence: 99%

Antibacterial Compounds from Mushrooms: A Lead to Fight ESKAPEE Pathogenic Bacteria?

et al. 2020

View full text Add to dashboard Cite

Infectious diseases are among the greatest threats to global health in the 21st century, and one critical concern is due to antibiotic resistance developed by an increasing number of bacterial strains. New resistance mechanisms are emerging with many infections becoming more and more difficult if not impossible to treat. This growing phenomenon not only is associated with increased mortality but also with longer hospital stays and higher medical costs. For these reasons, there is an urgent need to find new antibiotics targeting pathogenic microorganisms such as ESKAPEE bacteria. Most of currently approved antibiotics are derived from microorganisms, but higher fungi could constitute an alternative and remarkable reservoir of anti-infectious compounds. For instance, pleuromutilins constitute the first class of antibiotics derived from mushrooms. However, macromycetes still represent a largely unexplored source. Publications reporting the antibacterial potential of mushroom extracts are emerging, but few purified compounds have been evaluated for their bioactivity on pathogenic bacterial strains. Therefore, the aim of this review is to compile up-to-date data about natural products isolated from fruiting body fungi, which significantly inhibit the growth of ESKAPEE pathogenic bacteria. When available, data regarding modes of action and cytotoxicity, mandatory when considering a possible drug development, have been discussed in order to highlight the most promising compounds.

show abstract

A Payer Perspective of the Hospital Inpatient Additional Care Costs of Antimicrobial Resistance in France: A Matched Case–Control Study

Cited by 34 publications

References 32 publications

Quantifying the economic cost of antibiotic resistance and the impact of related interventions: rapid methodological review, conceptual framework and recommendations for future studies

Quantifying the economic cost of antibiotic resistance and the impact of related interventions: rapid methodological review, conceptual framework and recommendations for future studies

“Smart” Antimicrobial Nanocomplexes with Potential to Decrease Surgical Site Infections (SSI)

Antibacterial Compounds from Mushrooms: A Lead to Fight ESKAPEE Pathogenic Bacteria?

Contact Info

Product

Resources

About